Diabetes Drug Market Research Report – Global Forecast to 2023

Diabetes Drug Market Research Report – Global Forecast to 2023

ID: MRFR/Pharma/0654-HCRR | October, 2018 | Region: Global | 80 pages | Half-Cooked Research Reports

Global Diabetes Drug Market Research Report, Type of Diabetes (Type-1 And Type-2), By Administration (Oral, Intravenous, Other), By Drug Class (Insulin, Sensitizers, SGLT-2 Inhibitors, Alpha-Glucosidase Inhibitors), By End Users (Hospital & Clinics, Ambulatory Clinics) - Forecast to 2023


Market Scenario


Diabetes is a metabolic disorder in which the body glucose level is elevated. There are two type of diabetes namely type-1 diabetes and type-2 diabetes. During last decade there is a tremendous increase in the number of diabetic population. According to International Diabetes Federation, in 2016, it was estimated that 420 million adult population were suffering from diabetes which is increasing at the rate of 8.4% and is expected to reach 625 million by 2040. A number of different types of drugs are available in the market however, no available treatment can cure diabetes totally. The global diabetic drug market is majorly driven by increasing number of diabetic population. According to research, smoking increases the possibility of diabetes; more than 60% of the global population smokes, this has increased the risk of diabetes and contributed to the growth of the market. Moreover, increasing obese population, increasing healthcare expenditure, and strong encouragement from the government have also contributed to the growth of the market. To meet the increasing demand for the drugs government of different countries are providing support to manufacturers. Increasing government support will help to boost the market in coming future. However, cost issues, strict regulatory rules and long approval time for drugs may led to restrain the growth of the market.


The global diabetes drug market is expected to grow at a CAGR of 6.38% during forecasted period.


 


Intended Audience



  • Government and Private Hospitals

  • Blood banks and institutes

  • Biotechnological institutes

  • Pharmaceutical companies

  • Research and Development (R&D) Companies

  • Market Research and Consulting Service Providers

  • Medical Research Laboratories  


Figure 1:- Global diabetes drug market share, by region

diabetes drug market


Sources: WHO, annual reports, press release, white paper, and company presentation


Segmentation


The global diabetes drug market is segmented on the basis of types, route of administration, drug class, and end users.


On the basis of types, the market is segmented into type-1 diabetes and type-2 diabetes.


On the basis of route of administration, the market is segmented into oral, intravenous and other.


On the basis of drug class they are insulin, sensitizers, SGLT-2 inhibitors, alpha-glucosidase inhibitors, secretagogues, peptide analogs and others. Sensitizers are sub segmented into thiazolidinediones and biguanides. Secretagogues are further segmented into sulfonylureas and non-sulfonylureas


On the basis of end users, the market is segmented into hospital & clinics, ambulatory clinics and other. 


Regional Analysis


America dominates the global diabetes drug market owing to large diabetic patient population. According to the WHO, in 2016, 9.6% of total America population were suffering from diabetes. In addition to this, increasing number of obese people, changing lifestyle and increasing healthcare expenditure have boosted the growth of the market in America. Increasing cholesterol level and smoking increases the possibility of causing diabetes. According to the Centers for Disease Control and Prevention (2014), 73.5 million adults in the US had diagnosed with high cholesterol level. Furthermore, increasing awareness among the people regarding different monitoring procedures, rising awareness and well-developed technology have also contributed to the growth of the market.


Europe accounts for the second largest diabetes drug market, which is followed by Asia Pacific. Huge smoking population, availability of funds for research, and government support for research & development will drive the market in Europe.


Asia Pacific is the fastest growing region for the market due to the presence of a huge patient population, continuously developing economies, and increasing need for the better treatment.


On the other hand, the Middle East & Africa has the least share in the global diabetes drug market due to presence of poor economy especially in Africa region. Middle East holds the major share in the Middle East & Africa diabetes drug market owing to well-developed healthcare sector and huge healthcare expenditure. 


Research Methodology


Diabetes Drug Market-


Sources: WHO, annual reports, press release, white paper, and company presentation


Key Players for global diabetes drug market


The major player in the global diabetic drug market are Eli Lilly (US), Novo Nordisk (Denmark), Abbott (US), AstraZeneca (UK), Biocon (US), Sunpharma (India), Sanofi (France), Novartis (Switzerland), Merck & Co. (US), Pfizer (US), Daiichi Sankyo (Japan), Boehringer Ingelheim (Germany), Akros Pharma (US), Amgen (US), Adocia (France), Peptron (South Korea), Takeda (Japan).

TABLE OF CONTENT

Chapter 1. Report Prologue

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary research

3.4 Market Size Estimation

Chapter 4. Market Dynamics

4.1 Drivers

4.2 Restrains

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Technology Trends & Assessment

Chapter 5. Market Factor Analysis

5.1 Porters Five Forces Analysis

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

5.3 Investment Feasibility Analysis

5.4 Pricing Analysis

Chapter 6. Global Diabetes Drug Market, by Type

6.1 Introduction

6.2 Type-1 Diabetes

Market Estimates & Forecast, 2017 – 2023

6.3 Type-2 Diabetes

Market Estimates & Forecast, 2017 – 2023

Chapter 7. Global Diabetes Drug Market, by Administration

7.1 Introduction

7.2 Oral

Market Estimates & Forecast, 2017 – 2023

7.3 Intravenous

Market Estimates & Forecast, 2017 – 2023

7.4 Others

Chapter 8 Global Diabetes Drug Market, by End User

8.1 Introduction

8.2 Insulin

Market Estimates & Forecast, 2017 – 2023

8.3 Sensitizers

Market Estimates & Forecast, 2017 – 2023

8.4 SGLT-2 Inhibitors

Market Estimates & Forecast, 2017 – 2023

8.5 Alpha-Glucosidase Inhibitors

Market Estimates & Forecast, 2017 – 2023

Chapter 9 Global Diabetes Drug Market, by End User

9.1 Introduction

9.2 Hospitals & Clinics

Market Estimates & Forecast, 2017 – 2023

9.3 Ambulatory Clinics

Market Estimates & Forecast, 2017 – 2023

9.4 Others

Market Estimates & Forecast, 2017 – 2023

Chapter 10. Global Diabetes Drug Market, by Region

10.1 Introduction

10.2 America

10.2.1 North America

10.2.1.1 US

10.2.1.1 Canada

10.2.2 South America

10.3 Europe

10.3.1 Western Europe

10.3.1.1 Germany

10.3.1.2 France

10.3.1.3 Italy

10.3.1.4 Spain

10.3.1.5 UK

10.3.1.6 Rest of Western Europe

10.3.2 Eastern Europe

10.4 Asia Pacific

10.4.1 Japan

10.4.2 China

10.4.3 India

10.4.4 Australia

10.4.5 Republic of Korea

10.4.6 Rest of Asia Pacific

10.5 The Middle East & Africa

10.5.1 United Arab Emirates

10.5.2 Saudi Arabia

10.5.3 Oman

10.5.4 Kuwait

10.5.5 Qatar

10.5.6 Rest of the Middle East & Africa

Chapter 11 Company Landscape

11.1 Introduction

11.2 Market Share Analysis

11.3 Key Development & Strategies

11.3.1 Key Developments

Chapter 12 Company Profiles

12.1 Eli Lilly

12.1.1 Company Overview

12.1.2 Product Overview

12.1.3 Financials

12.1.4 SWOT Analysis

12.2 AstraZeneca

12.2.1 Company Overview

12.2.2 Product Overview

12.2.3 Financial Overview

12.2.4 Key Developments

12.2.5 SWOT Analysis

12.3 Abbott

12.3.1 Company Overview

12.3.2 Product Overview

12.3.3 Financial Overview

12.3.4 Key Development

12.3.5 SWOT Analysis

12.4 Biocon

12.4.1 Company Overview

12.4.2 Product/Business Segment Overview

12.4.3 Financial Overview

12.4.4 Key Development

12.4.5 SWOT Analysis

12.5 Sunpharma

12.5.1 Company Overview

12.5.2 Product Overview

12.5.3 Financial overview

12.5.4 Key Developments

12.6 Merck & Co., Inc.

12.6.1 Company Overview

12.6.2 Product Overview

12.6.3 Financial Overview

12.6.4 Key Developments

12.7 GlaxoSmithKline plc

12.7.1 Overview

12.7.2 Product Overview

12.7.3 Financials

12.7.4 Key Developments

12.7.5 SWOT Analysis

12.8 Others

Chapter 13 MRFR Conclusion

13.1 Key Findings

13.1.1 From CEO’s View Point

13.1.2 Unmet Needs of the Market

13.2 Key Companies to Watch

13.3 Prediction of Pharmaceutical industry

Chapter 14 Appendix





LIST OF TABLES

Table 1 Diabetes Drug Industry Synopsis, 2017 – 2023

Table 2 Global Diabetes Drug Market Estimates and Forecast, 2017 – 2023, (USD Million)

Table 3 Global Diabetes Drug Market by Region, 2017 – 2023, (USD Million)

Table 4 Global Diabetes Drug Market by Types, 2017 – 2023, (USD Million)

Table 5 Global Diabetes Drug Market by Administration, 2017 – 2023, (USD Million)

Table 6 Global Diabetes Drug Market by Drug Class, 2017 – 2023, (USD Million)

Table 7 Global Diabetes Drug Market by End Users, 2017 – 2023, (USD Million)

Table 8 North America Diabetes Drug Market by Types, 2017 – 2023, (USD Million)

Table 9 North America Diabetes Drug Market by Administration, 2017 – 2023, (USD Million)

Table 10 North America Diabetes Drug Market by Drug Class, 2017 – 2023, (USD Million)

Table 11 North America Diabetes Drug Market by End Users, 2017 – 2023, (USD Million)

Table 12 US Market by Types, 2017 – 2023, (USD Million)

Table 13 US Diabetes Drug Market by Administration, 2017 – 2023, (USD Million)

Table 14 US Diabetes Drug Market by Drug Class, 2017 – 2023, (USD Million)

Table 15 US Diabetes Drug Market by End Users, 2017 – 2023, (USD Million)

Table 16 Canada Market by Types, 2017 – 2023, (USD Million)

Table 17 Canada Diabetes Drug Market by Administration, 2017 – 2023, (USD Million)

Table 18 Canada Diabetes Drug Market by Drug Class, 2017 – 2023, (USD Million)

Table 19 Canada Diabetes Drug Market by End Users, 2017 – 2023, (USD Million)

Table 20 South America Market by Types, 2017 – 2023, (USD Million)

Table 21 South America Diabetes Drug Market by Administration, 2017 – 2023, (USD Million)

Table 22 South America Diabetes Drug Market by Drug Class, 2017 – 2023, (USD Million)

Table 23 South America Diabetes Drug Market by End Users, 2017 – 2023, (USD Million)

Table 24 Europe Market by Types, 2017 – 2023, (USD Million)

Table 25 Europe Diabetes Drug Market by Administration, 2017 – 2023, (USD Million)

Table 26 Europe Diabetes Drug Market by Drug Class, 2017 – 2023, (USD Million)

Table 27 Europe Diabetes Drug Market by End Users, 2017 – 2023, (USD Million)

Table 28 Western Europe Market by Types, 2017 – 2023, (USD Million)

Table 29 Western Europe Diabetes Drug Market by Administration, 2017 – 2023, (USD Million)

Table 30 Western Europe Diabetes Drug Market by End Users, 2017 – 2023, (USD Million)

Table 31 Eastern Europe Market by Types, 2017 – 2023, (USD Million)

Table 32 Eastern Europe Diabetes Drug Market by Administration, 2017 – 2023, (USD Million)

Table 33 Eastern Europe Diabetes Drug Market by Drug Class, 2017 – 2023, (USD Million)

Table 34 Eastern Europe Diabetes Drug Market by End Users, 2017 – 2023, (USD Million)

Table 35 Asia Pacific Market by Types, 2017 – 2023, (USD Million)

Table 36 Asia Pacific Diabetes Drug Market by Administration, 2017 – 2023, (USD Million)

Table 37 Asia Pacific Diabetes Drug Market by Drug Class, 2017 – 2023, (USD Million)

Table 38 Asia Pacific Diabetes Drug Market by End Users, 2017 – 2023, (USD Million)

Table 39 Middle East & Africa Market by Types, 2017 – 2023, (USD Million)

Table 40 Middle East & Africa Diabetes Drug Market by Administration, 2017 – 2023, (USD Million)

Table 41 The Middle East & Africa Diabetes Drug Market by Drug Class, 2017 – 2023, (USD Million)

Table 42 Middle East & Africa Diabetes Drug Market by End Users, 2017 – 2023, (USD Million)





LIST OF FIGURES

Figure 1 Research Process

Figure 2 Segmentation for Global Diabetes Drug Market

Figure 3 Segmentation Market Dynamics for Global Diabetes Drug Market

Figure 4 Global Diabetes Drug market Share, by Type 2016

Figure 5 Global Diabetes Drug market Share, by Administration 2016

Figure 6 Global Diabetes Drug Market by Drug Class, 2017 – 2023, (USD Million)

Figure 7 Global Diabetes Drug Market Share, by End Users, 2016

Figure 8 Global Diabetes Drug Market Share, by Region, 2016

Figure 9 North America Diabetes Drug Market Share, by Country, 2016

Figure 10 Europe Diabetes Drug Market Share, by Country, 2016

Figure 11 Asia Pacific Diabetes Drug Market Share, by Country, 2016

Figure 12 Middle East & Africa Diabetes Drug Market Share, by Country, 2016

Figure 13 Global Diabetes Drug Market: Company Share Analysis, 2016 (%)

Figure 14 Eli Lilly: Key Financials

Figure 15 Eli Lilly: Segmental Revenue

Figure 16 Eli Lilly: Geographical Revenue

Figure 17 AstraZeneca: Key Financials

Figure 18 AstraZeneca: Segmental Revenue

Figure 19 AstraZeneca: Geographical Revenue

Figure 20 Abbott: Key Financials

Figure 21 Abbott: Segmental Revenue

Figure 22 Abbott: Geographical Revenue

Figure 23 Sunpharma: Key Financials

Figure 24 Sunpharma: Segmental Revenue

Figure 25 Sunpharma: Geographical Revenue

Figure 26 Merck & Co., Inc.: Key Financials

Figure 27 Merck & Co., Inc.: Segmental Revenue

Figure 28 Merck & Co., Inc.: Geographical Revenue

Figure 29 GlaxoSmithKline plc: Key Financials

Figure 30 GlaxoSmithKline plc: Segmental Revenue

Figure 31 GlaxoSmithKline plc: Geographical Revenue

Figure 32 Sanofi: Key Financials

Figure 33 Sanofi: Segmental Revenue

Figure 34 Sanofi: Geographical Revenue